KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Non Operating Income (2017 - 2025)

Historic Non Operating Income for Neogenomics (NEO) over the last 16 years, with Q3 2025 value amounting to -$335000.0.

  • Neogenomics' Non Operating Income fell 20567.82% to -$335000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$219000.0, marking a year-over-year decrease of 22443.18%. This contributed to the annual value of -$379000.0 for FY2024, which is 15885.09% down from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Non Operating Income is -$335000.0, which was down 20567.82% from $482000.0 recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Non Operating Income registered a high of $730000.0 during Q2 2023, and its lowest value of -$4.9 million during Q1 2021.
  • For the 5-year period, Neogenomics' Non Operating Income averaged around -$276842.1, with its median value being -$1000.0 (2022).
  • Per our database at Business Quant, Neogenomics' Non Operating Income tumbled by 227668.16% in 2021 and then soared by 2420000.0% in 2025.
  • Neogenomics' Non Operating Income (Quarter) stood at -$930000.0 in 2021, then surged by 99.89% to -$1000.0 in 2022, then skyrocketed by 12500.0% to $124000.0 in 2023, then crashed by 447.58% to -$431000.0 in 2024, then grew by 22.27% to -$335000.0 in 2025.
  • Its Non Operating Income stands at -$335000.0 for Q3 2025, versus $482000.0 for Q2 2025 and $65000.0 for Q1 2025.